References
- Novak MJ, Tabrizi SJ. Huntington’s disease. BMJ 2010;340:c3109
- Spinney L. Uncovering the true prevalence of Huntington's disease. Lancet Neurol 2010;9:760-1
- National Institute of Neurological Disorders and Stroke. What is Huntington’s Disease? National Institutes of Heath, Bethesda MD, 2012. http://www.ninds.nih.gov/disorders/huntington/huntington.htm. Accessed March 6, 2012
- Cardoso F. Huntington disease and other choreas. Neurol Clin 2009;27:719-36
- Roos RAC. Huntington’s disease: a clinical review. Orphanet J Rare Dis 2010;5:40
- Shoulson IF, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3
- Rosas HD, Reuter M, Doros G, et al. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study. Mov Disord 2011;26:1691-7
- Mayo Clinic. Huntington’s disease. Treatment and drugs. Mayo Foundation for Medical Education and Research (MFMER), Rochester, MN, 2011. http://www.mayoclinic.com/health/huntingtons-disease/DS00401/DSECTION=treatments%2Dand%2Ddrugs. Accessed March 6, 2012
- Murman DL, Chen Q, Colucci PM, et al. Comparison of healthcare utilization and direct costs in three degenerative dementias. Am J Geriatr Psychiatry 2002;10:328-36
- McCabe MP, O'Connor EJ. A longitudinal study of economic pressure among people living with a progressive neurological illness. Chronic Illn 2009;5:177-83
- Dubinsky RM. No going home for hospitalized Huntington's disease patients. Mov Disord 2005;20:1316-22
- Thomson Reuters MarketScan Research Database. Thomson Reuters Healthcare, Inc., Ann Arbor, MI, 2012 http://thomsonreuters.com/products_services/healthcare/healthcare_products/pharmaceuticals/epidemiology_res/mktscan_res_db. Accessed on January 12, 2012
- Buck CJ. ICD-9-CM 2011 Professional Edition for Physicians, Vols 1&2: Compact: 1st edn. American Medical Association, Chicago, IL. 2010
- Bureau of Labor Statistics. Consumer Price Index. Washington, DC, 2011. http://www.bls.gov/cpi. Accessed on October 1, 2011
- Costa N, Derumeaux H, Rapp T, et al. Methodological considerations in cost of illness studies on Alzheimer disease. Health Econ Rev 2012;2:18
- Joyce AT, Zhao Y, Bowman L, et al. Burden of illness among commercially insured patients with Alzheimer’s disease. Dement 2007;3:204-10
- Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
- Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson's disease. Mov Disord 2005;20:1449-54
- Fillit H, Hill JW, Futterman R. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam Med 2002;34:528-35
- Gilden DM, Kubisiak J, Zbrozek AS. The economic burden of Medicare-eligible patients by multiple sclerosis type. Value Health 2011;14:61-9
- Dworkin RH, White R, O'Connor AB, et al. Health care expenditure burden of persisting herpes zoster pain. Pain Med 2008;9:348-53
- van Dijk JG, van der Velde EA, Roos RA, et al. Juvenile Huntington Disease. Hum Genet 1986;73:235-9